Last reviewed · How we verify
Medical air equivalent
At a glance
| Generic name | Medical air equivalent |
|---|---|
| Sponsor | University of Birmingham |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of LPG and Ventilation Interventions on Reducing HAP and Improving Cardiopulmonary Health (NA)
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- Air Pollution and Development in the Boricua Youth Study (NA)
- Interventions for Patients With Alzheimer's Disease and Dysphagia (NA)
- Graded Exercise Hypoxia Testing
- Radiofrequency and Exercise-based Rehabilitation on Symptoms Associated With Pelvic Floor Dysfunctions in Breast Cancer (NA)
- A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD) (PHASE3)
- Fundamental and Clinical Study of Cochlear Synaptopathy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Medical air equivalent CI brief — competitive landscape report
- Medical air equivalent updates RSS · CI watch RSS
- University of Birmingham portfolio CI